Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II study of SYS6023 combination therapy in unresectable locally advanced or metastatic breast cancer
CTR20261826Phase 2Active
- Sponsor
- CSPC Megalith Biopharmaceutical Co., Ltd.
- Start
- Jun 2026
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 2 trial of SYS6023 in breast cancer, sponsored by CSPC Megalith Biopharmaceutical Co., Ltd.. Started Jun 2026; status: active.
02
Drugs
SYS6023
03
Conditions
breast cancer
Beyond the preview
Go deeper on CTR20261826.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20261826.